RapiMix^TM

Indication:
Type 1 and Type 2 Diabetes Mellitus, Gestational Diabetes Mellitus.

Dosage & Administration:
RapiMix^TM is an insulin analog with an earlier onset and intermediate duration of action in comparison to the basal human insulin premix. The addition of protamine to the rapid-acting insulin aspart results in insulin activity that is 30% short-acting and 70% long-acting. RapiMix^TM is typically dosed on a twice-daily basis. The dosage of RapiMix^TM must be individualized. RapiMix^TM should appear uniformly white and cloudy. Do not use it if it looks clear or if it contains solid particles.
RapiMix^TM should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. RapiMix^TM has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation. RapiMix^TM should not be administered intravenously or used in insulin infusion pumps. Dose regimens of RapiMix^TM will vary among patients and should be determined by the doctors with the patient’s recommended glucose treatment goals, metabolic needs, eating habits, and other lifestyle variables.

Preparation:
Rapimix^TM 30/70 Injection: Each box contains 1 vial of 3 ml Rapimix^TM.
Rapimix^TM 30/70 Pen Cartridge: Each box contains 1 cartridge of 3 ml Rapimix^TM.